May 20, 2026 -- When Novartis unilaterally terminated its manufacturing lease agreement with Chinese CDMO Porton Pharma Solutions at its Menges campus in Slovenia earlier this month, the pharmaceutical industry took notice. The Swiss drugmaker is seeking approximately 54.7 million euros (roughly $64 million) in damages and service charges, while Porton has publicly stated it disagrees with Novartis' position and remains in negotiations. The dispute offers critical lessons for pharmaceutical suppliers, CDMOs, and any company involved in cross-border manufacturing partnerships.
The conflict centers on Porton's B30 production facility at the Novartis Menges campus in Slovenia. According to Novartis, Porton failed to complete regulatory filings for the facility, which delayed construction and violated the terms of their agreement. Porton, for its part, has indicated that compliance issues with the facility's preliminary regulatory submissions forced a delay in subsequent investment -- a situation the company attributes to regulatory complexity rather than willful non-performance.
The Novartis-Porton dispute highlights a persistent challenge in international pharmaceutical manufacturing: the gap between regulatory requirements in different jurisdictions. When a Chinese CDMO operates a facility on European soil under the supervision of a Swiss pharmaceutical company, the regulatory landscape becomes extraordinarily complex.
For CDMOs and their pharmaceutical clients, this case underscores several critical risk factors:
For API and intermediate suppliers operating in the CDMO ecosystem, the Novartis-Porton case offers actionable takeaways:
Due diligence on partner capabilities: Before entering manufacturing agreements, pharmaceutical companies must rigorously assess not only a CDMO's technical capabilities but also its regulatory track record in the relevant jurisdictions. A facility's GMP history, inspection outcomes, and regulatory filing success rate should be weighted equally with cost and capacity considerations.
Contractual clarity on regulatory obligations: Manufacturing agreements must explicitly delineate which party is responsible for each regulatory milestone. Ambiguity in these provisions -- particularly around facility licensing, environmental compliance, and quality system validation -- creates the kind of exposure that can lead to costly disputes.
Phased investment structures: The risk of large-scale upfront commitments in cross-border manufacturing arrangements argues for phased investment models tied to regulatory milestones. CDMOs that demonstrate regulatory competence at each phase earn the right to expanded partnerships, reducing the financial exposure for both parties.
Quality system harmonization: The gap between Chinese and European GMP standards, while narrowing, remains a significant factor in cross-border CDMO partnerships. Suppliers must invest in harmonizing their quality systems to meet the expectations of both their CDMO partners and the end-market regulatory authorities.
The Novartis-Porton dispute occurs against the backdrop of a rapidly evolving CDMO market. Global pharmaceutical companies are increasingly relying on external manufacturing partners to support expanding pipelines -- particularly in high-growth areas such as GLP-1 therapies, antibody-drug conjugates (ADCs), and cell and gene therapies.
Novartis itself has been a major investor in manufacturing capacity, recently finalizing plans for its seventh new U.S. manufacturing and R&D facility. The company's decision to terminate the Porton arrangement suggests a strategic realignment toward more direct control over critical manufacturing capabilities -- a trend that may accelerate across the industry as supply chain resilience becomes a board-level priority.
For CDMOs competing for pharmaceutical manufacturing contracts, the Novartis-Porton case sends a clear message: regulatory competence is no longer optional. Companies that can demonstrate flawless regulatory execution across multiple jurisdictions -- and that build contractual frameworks reflecting this competence -- will be best positioned to capture the growing demand for contract manufacturing services.
The dispute also highlights the importance of supply chain diversification. Pharmaceutical companies that concentrate critical manufacturing capabilities with a single CDMO partner -- particularly in a cross-border arrangement -- face significant risk if the relationship deteriorates. Building redundant supply relationships and maintaining the optionality to shift production between facilities are essential elements of resilient pharmaceutical supply chain strategy.
For API and intermediate suppliers, the Novartis-Porton situation reinforces the value of direct relationships with pharmaceutical companies, rather than relying solely on CDMO intermediaries. When CDMO partnerships encounter difficulties, pharmaceutical companies may seek to establish direct supply relationships with the raw material providers who can offer continuity of supply regardless of CDMO arrangements.
As the pharmaceutical industry continues to navigate the complexities of global manufacturing, the Novartis-Porton dispute serves as a reminder that the strongest partnerships are built on regulatory expertise, contractual clarity, and mutual accountability -- not just competitive pricing.
